Tiziana Signs MOU with KAIMRC for RRMS Combination Trial; Phase 2 na-SPMS Data Due October
TLSA is trading near its 52-week low of $0.762 (7.5% above the low).
Summary
Tiziana signed an MOU with KAIMRC and partners to study intranasal foralumab plus anti-CD20 therapy in RRMS patients with poor response to anti-CD20 alone. The company also confirmed Phase 2 na-SPMS results are expected in October 2026.
Key Events · Product Development and Regulatory · TLSA
-
MOU Signed with KAIMRC
A Memorandum of Understanding was signed with King Abdullah International Medical Research Center (KAIMRC), KSAU-HS, and the Foundation for Neurologic Diseases to collaborate on a clinical trial of intranasal foralumab combined with anti-CD20 therapy in RRMS patients responding poorly to anti-CD20 alone.
-
New MS Indication Added
The planned RRMS trial represents an additional multiple sclerosis type beyond the company's ongoing non-active Secondary Progressive MS (na-SPMS) program, broadening the foralumab pipeline.
-
Phase 2 na-SPMS Readout in October
CEO Ivor Elrifi confirmed the Phase 2 na-SPMS trial remains blinded with results expected in October 2026, a near-term catalyst for the stock.
-
No Financial Terms Disclosed
The MOU is non-binding and no funding, milestone, or cost-sharing terms were disclosed, making the partnership's financial impact uncertain.
Analysis · TLSA · Life Sciences
A Saudi Arabian research partnership broadens the foralumab program into relapsing-remitting MS, adding a second indication beyond the ongoing na-SPMS trial. While the MOU is non-binding and carries no disclosed financial terms, it validates the platform and opens a new clinical pathway. The more immediate catalyst is the Phase 2 na-SPMS readout expected in October 2026, which the company explicitly reaffirms remains blinded and on track.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.4% of the 1637 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLSA was trading at $0.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.8M. The 52-week trading range was $0.76 to $2.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.